|
Published by Health Affairs on
June 18, 2020
Contact: CMS Media
Relations
(202) 690-6145 | CMS Media Inquiries
CMS’s
Proposed Rule On Value-Based Purchasing For Prescription Drugs: New Tools
For Negotiating Prices For The Next Generation of Therapies
The Trump Administration has delivered
significant policy advancements to lower the price of drugs and spur
greater competition and innovation in the American health care system. As a
result of actions by the Centers for Medicare and Medicaid Services (CMS),
the average basic premium for Medicare Part D prescription drug plans was
projected to decline 13.5 percent since 2017, to the
lowest level in seven years, saving beneficiaries about $1.9 billion in
premium costs over that time. Most recently, in March, CMS announced the
Senior Savings Model, where participating enhanced Part D prescription drug
plans across the country will provide Medicare beneficiaries access to a
broad set of insulins at a maximum $35 copay for a month’s supply, saving
beneficiaries on average 66 percent per year.
Today, we are announcing another significant step
in this fight through a proposed overhaul of Medicaid regulations that
have long inhibited payment innovation among prescription drugs across the
entire system.
To read the full Health Affairs blog, go to:
|
No comments:
Post a Comment